Therapeutic options for the treatment ofallergic rhinitis include environmental modifications to decre ase exposure to allergens, pharmacotherapy, and immunotherapy for those patients who do not expe rience satisfactory relief of their symptoms with medical management. Skin testing is the best established and most sensitive indicator of allergic disease. Several techniques are currently in use to identify pertinent antigens in the treatment of inhalant allergies. We describ e the various skin testing techniques that are associated with such inhalant allergies. Quantification of skin reactivity to formulate a successful antigen vial for effective immunotherapy is necessary in the management of allergic diseas e.
Introduction
Allergic rhinitis is the fifth most prevalent chronic condition in the United States, affecting an estimated 36 million Americans and accounting for approximately 3 million lost work days and 2 million lost school days.":' The economic impact of allergic rhinitis in the United States is high by any standard. According to one population survey, the estimated cost of physician visits and medications is $3.5 billion annually." Allergic rhinitis is an inflammatory condition characterized by an immunoglobulin E (IgE) -mediated reaction to airborne allergens that results in inflammation of the nasal mucosa and other target organs. Approximately 50 % of the patients encountered by otolaryngologists have some type of allergy as a major cause of, or at least a contributing factor in, the problem that prompted their visit. Because the head is the most common portal of entry ("the shock organ") for inhalant sensitivities-and con- From 
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sidering the associated disorders (chronic or recurrent rhinosinusitis, otitis media, laryngitis, and vertigo)-the otolaryngologist is uniquely qualified by way of medical and surgical training to diagnose and select the most appropriate and effective means of managing upper respiratory allergic disease. Medical therapeutic options for allergic rhinosinusitis include environmental control, decongestants, antihistamines, other antimediator drugs, and immunotherapy. Immunotherapy is indicated for those patients who do not experience sufficient symptom relief medically. It is important to note that the goals of allergy testing and immunotherapy include the accurate identification and quantification of each antigen to which the patient is allergic so that the therapeutic approach can be designed to provide symptom relief in a safe and expedient manner.
Successful immunotherapy is defined by a decrease in a patient's allergic reactivity and by the relief of symptoms of an IgE-mediated allergy. Although several theories have been proposed to explain the clinical efficacy of immunotherapy, the exact mechanisms by which it is effective are not completely understood, and they are the subject of much debate. It is known that a decrease occurs in circulating allergen-specific IgE even when there is a temporary rise early in the course of immunotherapy." This effect can be secondary to the suppression of Thelper cells or the excitation of T-suppressor lymphocytes in modulating the formation of IgE. 6 It is also believed that the formation of immunoglobulin-G-blocking antibodies (specifically IgG4) is correlated with successful allergy management because an increase in specific IgG4 has been associated with a good clinical response by some investigators. ' However, there is no definitive conclusion regarding these antibodies because other studies have not confirmed these findings. s Regardless of what its direct immunologic effects are , immunotherapy is an effective management tool in the treatment of allergic rhinosinusitis. Because the effectiveness of immunotherapy does not occur independently of the diag-nostic methodology, herein we descri be the various types of testing techniques for inhalant allergies.
Skin testing techniques
Skin testing is the best-established and most sensitive indicator of allergic disease. It relies on the reac tivity and sensitivi ty of mast cells that have bee n sens itized with specific IgE to reflec t allergen sensitivity. Skin testi ng involves intro ducing specific antigens onto or into the skin by way of scratc h, prick, and intradermal tests.
Scratch testing . Scratc h testing is insensitive, painful, not reproducible, and no longer a reco mmended diagnostic procedure."
Prick testing. Prick tests were first described by Lewis and Grant in 1926, 10 and they were popul arized by Pepys in the 1970s .1 1 Prick tests are super ior to scratch tests because they are more sensitive, more repro ducible, and correlate better with intradermal tests." They ca n be performed in a variety of ways, but the type of testing greatly influences the results.
In general, the techn ique involves introd ucing a predetermined strength of antigen (usually concentrate) into the skin and interpreting the wheal-and-flare response after 10 to 20 minutes. Thi s response is graded from 0 to 4+, dependin g on the size of the wheal and the degree of erythema. The classic prick test was first performed with a 25-gauge hypodermic syringe needle." The needle was introduced about I mm deep into the skin at an angle through a drop let of antigen . The ski n was then lifted and tented to allow more antigen entry . This procedure is subject to significant variabi lity because of the difficul ty of precisely reproducing the depth of penetration , the amount of force used, and the amount of skin lifting.
The vertical prick puncture with a single point was developed by Brown et al in an attem pt to better standardize prick tests." Th is procedure involves using a guard that prevents penetration of the needle into the ski n beyond a predete rmined depth; also, no skin lifting is used. Other puncture tests have been developed in an effort to contro l the var iabili ty of prick test ing, yet detectable differences rema in in the reprod ucib ility amo ng them." More rece ntly, multiprick devices have been developed that are believed to be more sensitive and less techniqu edependent than single prick tests."
The major disadvantages of prick testing are the lack of standard ization and the lack of quantification. Th is test does not determine the precise level of sensitivity for specific antigens. In addit ion, it misses low-sensitivity responses beca use there is no opportunity to detect allergic disease at sensitivities below the concentration of the antigen that is used. Because of this lack of quantification, immunotherapy based on skin prick tes ting must be started at doses sufficiently diluted to minimize the possibility of a systemic reaction. Antigens appropriate for inclusion in therapy are generally divided into high-and low-sensitiv -ity groups base d primari ly on the reaction observe d durin g prick testing. All low-sensitivity antigens are mixed at an identi cal concen tration (usually 1:20,000 w/v), and those that are believed to be high-sensitivity antigens are then mixed in a separate via l at concentrations of 1:200,000 w/v . The antige ns are further diluted in direct proportion to the number of antigens placed in each treatment vial.
One drawback associated with treatment based on prick testing is the length of time required to achieve maximum dosing; mon ths to years might be needed to reach these levels. Moreover, because of the different antigen sensitiv ities, a therapy-lim iting response from one antige n will occur while other antigens in the same treatm ent vial will remain at far-from-optimal dosages. Failure to reac h therapeutic concentratio ns for all pertinent antige ns will resu lt in a lack of allergic symptom relief and treat ment fail ure.
Intradermal testing. Skin endpoint titra tion (SET) testing, also referred to as serial dilution quantitative intradermal testing, is a modification of intradermal testing that uses spec ific antigen dilut ions to establish the minimum amount of antigen required to produce a positive skin test. SET differs from other ski n tests in that it is primarily designed to be a quantit ative rather than a qualitative test of allerge n sensitivity. Although it is possi ble to perform semi quantitative skin testing with prick techniques," it is not commonly done beca use the range of testing is techni cally limited by the high concentrations of antigen requ ired for these epic utaneous tests.
SET uses a 1:5 dilution of antigens. The physician starts with a concentrate (I :20 w/v) and sequentially dilutes it in fivefo ld increments, which by convention have been labeled dilu tion No. I (1 : 100), dilution No . 2 (I :500), diluti on No. 3 (I :2,500), dilut ion No.4 (I : 12,500), dilution No. 5 (I :62,500), and dilution No.6 (I :3 12,500).
The procedure begins with the injection of a very dilu te mixture (usua lly dilution No.6) into the skin, which creates a 4-mm wheal that grows to 5 mm by diffusion. The wheal is obse rved for 10 minutes. If the wheal does not enlarge by at least 2 mm (i.e., fro m 5 to 7 mm), the next stronger dilution (dilution No.5 ) is injected and the wheal is agai n obse rved for grow th. Thi s process is repeated until a 2-mm wheal growth is obser ved. Confirmation that the correct concentration has been identified is obtained when the next more-concentrated dilution increases the size of the wheal by an addi tional 2 mm (i.e., from 7 to 9 mm) with in 10min utes ("t he confirmatory whea l"). The "endpoint" is defined as the first wheal that increases in size by 2 mm, followed by a confirmatory wheal. The endpoint concentration iden tifies not only the antigens to which the patient is allerg ic, but also the patient's level of sens itivity to them, providing a safe point for the initiation of immunotherapy. The Ex ert medical information so fast, you'll have to monitor your own heart rate.
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Once the different antigens have been evaluated for reactivity in this manner, a treatment vial can be created that will include each clinic ally pertinent antigen at its individual endpoint concentration. Immunotherapy is usually started with an intradermal test dose of 0.05 ml from the treatment vial, follow ed by weekly inj ections escalating by 0.05 ml each time until the symptomrelieving dose (the highest dose of antigen that provides maximum relief of symptoms without producing any significant local or systemic reaction s) is achieved ."
The advantages of SET are its ability to: 1) deliver antigen at a safe concentration, but close to the maximum tolerated level at the onset of treatment, 2) shorten the length of time needed to achieve symptom relief, and 3) provide a way to increase the concentration of each antigen based on the individual level of sensitivity. This technique thereby avoids the chance that a particularly high-sensitivity antigen will cause a local or systemic reaction during dose escalation, which would limit the progression of the entire series before therapeutic levels are attained for other important but less-sensitive antigen s.
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Incl uding: Quantification of skin reactivity by intradermal testing with the SET techniqu e provides the most accurate assessment of a patient' s hypersensitivity. For an antigen to elicit a beneficial immunologic response, it must be administered in large enough doses to stimulate a therapeutic response. 19 Only those skin tests that can quantify the patient ' s sensitivity to each individual allergen will provide the information necessary to formulate a treatment program that will achieve optimal therapeutic results." The methodology used in skin testing has a direct relationship on our ability to identify the optimum therapeutic dosage of each antigen and therefore to achieve the ultimate success with immunotherapy.
